Sequence selectivity of the cleavage sites induced by topoisomerase i inhibitors: A molecular dynamics study

Nucleic Acids Research

Volumn 41, Issue 22, 2013, Pages 10010-10019

  Siu, Fung Ming ^a,b   Pommier, Yves ^c  

^a SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CAMPTOTHECIN; ISOQUINOLINE DERIVATIVE; LMP 776; LYSINE; NUCLEOTIDE; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA CLEAVAGE; DNA SEQUENCE; DRUG BINDING; DRUG STRUCTURE; ENERGY; HYDROGEN BOND; MATHEMATICAL ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DNA BINDING; STRUCTURE ANALYSIS;

BASE SEQUENCE; CAMPTOTHECIN; DNA; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I; MOLECULAR DYNAMICS SIMULATION; PROTEIN STRUCTURE, TERTIARY; TOPOISOMERASE I INHIBITORS;

EID: 84890357684     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkt791     Document Type: Article

References (78)

1. Pommier, Y. and Marchand, C. (2012) Interfacial inhibitors: targeting macromolecular complexes. Nat. Rev. Drug. Discov., 11, 25-36.
2. Pommier, Y., Leo, E., Zhang, H. and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol., 17, 421-433.
3. Antony, S., Agama, K.K., Miao, Z.H., Takagi, K., Wright, M.H., Robles, A.I., Varticovski, L., Nagarajan, M., Morrell, A., Cushman, M. et al. (2007) Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res., 67, 10397-10405.
4. Wang, X., Zhou, X. and Hecht, S.M. (1999) Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry, 38, 4374-4381.
5. Oussedik, K., Francois, J.C., Halby, L., Senamaud-Beaufort, C., Toutirais, G., Dallavalle, S., Pommier, Y., Pisano, C. and Arimondo, P.B. (2010) Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins. FASEB J., 24, 2235-2244.
6. Arimondo, P.B., Laco, G.S., Thomas, C.J., Halby, L., Pez, D., Schmitt, P., Boutorine, A., Garestier, T., Pommier, Y., Hecht, S.M. et al. (2005) Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides. Biochemistry, 44, 4171-4180.
7. Baranello, L., Bertozzi, D., Fogli, M.V., Pommier, Y. and Capranico, G. (2010) DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1a gene locus. Nucleic Acids Res., 38, 159-171.
8. Vekhoff, P., Duca, M., Guianvarc'h, D., Benhida, R. and Arimondo, P.B. (2012) Sequence-specific base pair mimics are efficient topoisomerase IB inhibitors. Biochemistry, 51, 43-51.
9. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K.W. and Pommier, Y. (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Bio. Chem., 266, 20418-20423.
10. Jaxel, C., Kohn, K.W. and Pommier, Y. (1988) Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res., 16, 11157-11170.
11. Kjeldsen, E., Mollerup, S., Thomsen, B., Bonven, B.J., Bolund, L. and Westergaard, O. (1988) Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage. J. Mol. Biol., 202, 333-342.
12. Porter, S.E. and Champoux, J.J. (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res., 17, 8521-8532.
13. Solier, S., Barb, J., Zeeberg, B.R., Varma, S., Ryan, M.C., Kohn, K.W., Weinstein, J.N., Munson, P.J. and Pommier, Y. (2010) Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res., 70, 8055-8065.
14. Capranico, G., Marinello, J. and Baranello, L. (2010) Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity. Biochim. Biophys. Acta, 1806, 240-250.
15. Roux, B. (1995) The calculation of the potential of mean force using computer simulations. Comp. Phys. Commun., 91, 275-282.
16. Staker, B.L., Hjerrild, K., Feese, M.D., Behnke, C.A., Burgin, A.B. Jr and Stewart, L. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl Acad. Sci. USA, 99, 15387-15392.
17. Staker, B.L., Feese, M.D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L. and Burgin, A.B. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem., 48, 2336-2345.
18. Ivanova, B. and Spiteller, M. (2012) Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex. Biopolymers, 97, 134-144.
19. Laco, G.S. (2011) Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives. PLoS One, 6, e24314.
20. Drwal, M.N., Agama, K., Wakelin, L.P., Pommier, Y. and Griffith, R. (2011) Exploring DNA topoisomerase I ligand space in search of novel anticancer agents. PLoS One, 6, e25150.
21. Lauro, G., Romano, A., Riccio, R. and Bifulco, G. (2011) Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. J. Nat. Prod., 74, 1401-1407.
22. Lauria, A., Ippolito, M. and Almerico, A.M. (2007) Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database. J. Mol. Model., 13, 393-400.
23. Chillemi, G., Coletta, A., Mancini, G., Sanna, N. and Desideri, A. (2010) An amber compatible molecular mechanics force field for the anticancer drug topotecan. Theor. Chem. Acc., 127, 293-302.
24. Mancini, G., D'Annessa, I., Coletta, A., Sanna, N., Chillemi, G. and Desideri, A. (2010) Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I-DNA complex. PLoS One, 5, e10934.
25. Sanna, N., Chillemi, G., Grandi, A., Castelli, S., Desideri, A. and Barone, V. (2005) New hints on the Ph-driven tautomeric equilibria of the topotecan anticancer drug in aqueous solutions from an integrated spectroscopic and quantum-mechanical approach. J. Am. Chem. Soc., 127, 15429-15436.
26. Case, D.A., Cheatham, T.E. III, Darden, T., Gohlke, H., Luo, R., Merz, K.M. Jr, Onufriev, A., Simmerling, C., Wang, B. and Woods, R.J. (2005) The Amber biomolecular simulation programs. J. Comput. Chem., 26, 1668-1688.
27. Perez, A., Marchan, I., Svozil, D., Sponer, J., Cheatham, T.E. III, Laughton, C.A. and Orozco, M. (2007) Refinement of the AMBER force field for nucleic acids: improving the description of a/g conformers. Biophys. J., 92, 3817-3829.
28. Perez, A., Lankas, F., Luque, F.J. and Orozco, M. (2008) Towards a molecular dynamics consensus view of B-DNA flexibility. Nucleic Acids Res., 36, 2379-2394.
29. Cao, Z.W., Xue, Y., Han, L.Y., Xie, B., Zhou, H., Zheng, C.J., Lin, H.H. and Chen, Y.Z. (2004) MoViES: molecular vibrations evaluation server for analysis of fluctuational dynamics of proteins and nucleic acids. Nucleic Acids Res., 32, W679-W685.
30. Maffeo, C., Luan, B. and Aksimentiev, A. (2012) End-to-end attraction of duplex DNA. Nucleic Acids Res., 40, 3812-3821.
31. Darden, T., York, D. and Pedersen, L.G. (1993) Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. J. Chem. Phys., 98, 10089-10092.
32. Ryckaert, J.P., Ciccotti, G. and Berendsen, H.J.C. (1977) Numericalintegration of cartesian equations of motion of a system with constraints: molecular dynamics of N-alkanes. J. Comp. Phys., 23, 327-341.
33. Chu, W.T., Zhang, J.L., Zheng, Q.C., Chen, L. and Zhang, H.X. (2013) Insights into the folding and unfolding processes of wildtype and mutated SH3 domain by molecular dynamics and replica exchange molecular dynamics simulations. PLoS One, 8, e64886.
34. Humphrey, W., Dalke, A. and Schulten, K. (1996) VMD: visual molecular dynamics. J. Mol. Graph., 14, 33-38, 27-38.
35. Hess, B., Kutzner, C., van der Spoel, D. and Lindahl, E. (2008) GROMACS 4: algorithms for high efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput., 4, 435-447.
36. Hess, B. (2002) Convergence of sampling in protein simulations. Phys. Rev. E, 65, 031910.
37. Chillemi, G., D'Annessa, I., Fiorani, P., Losasso, C., Benedetti, P. and Desideri, A. (2008) Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. Nucleic Acids Res., 36, 5645-5651.
38. Onufriev, A., Bashford, D. and Case, D.A. (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins, 55, 383-394.
39. Gohlke, H., Kiel, C. and Case, D.A. (2003) Insights into proteinprotein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J. Mol. Biol., 330, 891-913.
40. Hou, T., Zhang, W., Case, D.A. and Wang, W. (2008) Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. J. Mol. Biol., 376, 1201-1214.
41. Balius, T.E. and Rizzo, R.C. (2009) Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry, 48, 8435-8448.
42. McGillick, B.E., Balius, T.E., Mukherjee, S. and Rizzo, R.C. (2010) Origins of resistance to the HIVgp41 viral entry inhibitor T20. Biochemistry, 49, 3575-3592.
43. Zoete, V. and Michielin, O. (2007) Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MMGBSA: application to the TCR-p-MHC complex. Proteins, 67, 1026-1047.
44. Lee, V.S., Tue-ngeun, P., Nangola, S., Kitidee, K., Jitonnom, J., Nimmanpipug, P., Jiranusornkul, S. and Tayapiwatana, C. (2010) Pairwise decomposition of residue interaction energies of single chain Fv with HIV-1 p17 epitope variants. Mol. Immunol., 47, 982-990.
45. Grossfield, A. WHAM: The Weighted Histogram Analysis Method, version 2.0.7.
46. Xiao, X. and Cushman, M. (2005) An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNAtopoisomerase I ternary cleavage complexes. J. Am. Chem. Soc., 127, 9960-9961.
47. Siu, F.M. and Che, C.M. (2008) Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study. J. Am. Chem. Soc., 130, 17928-17937.
48. Redinbo, M.R., Stewart, L., Champoux, J.J. and Hol, W.G. (1999) Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. J. Mol. Biol., 292, 685-696.
49. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J. and Laco, G.S. (1999) Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat., 2, 307-318.
50. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J. and Hol, W.G. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 279, 1504-1513.
51. Wang, L.F., Ting, C.Y., Lo, C.K., Su, J.S., Mickley, L.A., Fojo, A.T., Whang-Peng, J. and Hwang, J. (1997) Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res., 57, 1516-1522.
52. Fujimori, A., Harker, W.G., Kohlhagen, G., Hoki, Y. and Pommier, Y. (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55, 1339-1346.
53. Sirikantaramas, S., Yamazaki, M. and Saito, K. (2008) Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proc. Natl Acad. Sci. USA, 105, 6782-6786.
54. Fiorani, P., Tesauro, C., Mancini, G., Chillemi, G., D'Annessa, I., Graziani, G., Tentori, L., Muzi, A. and Desideri, A. (2009) Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. Nucleic Acids Res., 37, 6849-6858.
55. Chillemi, G., Fiorani, P., Castelli, S., Bruselles, A., Benedetti, P. and Desideri, A. (2005) Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study. Nucleic Acids Res., 33, 3339-3350.
56. Fiorani, P., Bruselles, A., Falconi, M., Chillemi, G., Desideri, A. and Benedetti, P. (2003) Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J. Bio. Chem., 278, 43268-43275.
57. Scaldaferro, S., Tinelli, S., Borgnetto, M.E., Azzini, A. and Capranico, G. (2001) Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I. Chem. Biol., 8, 871-881.
58. Stewart, L., Ireton, G.C. and Champoux, J.J. (1997) Reconstitution of human topoisomerase I by fragment complementation. J. Mol. Biol., 269, 355-372.
59. Pommier, Y. and Cushman, M. (2009) The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol. Cancer Ther., 8, 1008-1014.
60. Fukasawa, K., Komatani, H., Hara, Y., Suda, H., Okura, A., Nishimura, S. and Yoshinari, T. (1998) Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506. Int. J. Cancer, 75, 145-150.
61. Teicher, B.A. (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem. Pharm., 75, 1262-1271.
62. Marco, E., Laine, W., Tardy, C., Lansiaux, A., Iwao, M., Ishibashi, F., Bailly, C. and Gago, F. (2005) Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J. Med. Chem., 48, 3796-3807.
63. Antony, S., Jayaraman, M., Laco, G., Kohlhagen, G., Kohn, K.W., Cushman, M. and Pommier, Y. (2003) Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res., 63, 7428-7435.
64. Stewart, L., Ireton, G.C. and Champoux, J.J. (1999) A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J. Bio. Chem., 274, 32950-32960.
65. Losasso, C., Cretaio, E., Palle, K., Pattarello, L., Bjornsti, M.A. and Benedetti, P. (2007) Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality. J. Bio. Chem., 282, 9855-9864.
66. Losasso, C., Cretaio, E., Fiorani, P., D'Annessa, I., Chillemi, G. and Benedetti, P. (2008) A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance. Nucleic Acids Res., 36, 5635-5644.
67. Gongora, C., Vezzio-Vie, N., Tuduri, S., Denis, V., Causse, A., Auzanneau, C., Collod-Beroud, G., Coquelle, A., Pasero, P., Pourquier, P. et al. (2011) New Topoisomerase I mutations are associated with resistance to camptothecin. Mol. Cancer, 10, 64.
68. Laco, G.S. and Pommier, Y. (2008) Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition. Biochem. J., 411, 523-530.
69. Frohlich, R.F., Andersen, F.F., Westergaard, O., Andersen, A.H. and Knudsen, B.R. (2004) Regions within the N-terminal domain of human topoisomerase I exert important functions during strand rotation and DNA binding. J. Mol. Biol., 336, 93-103.
70. Vassallo, O., Castelli, S., D'Annessa, I., della Rocca, B.M., Stella, L., Knudsen, B.R. and Desideri, A. (2011) Evidences of a natively unfolded state for the human topoisomerase IB N-terminal domain. Amino Acids, 41, 945-953.
71. Chillemi, G., Redinbo, M., Bruselles, A. and Desideri, A. (2004) Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics. Biophys J., 87, 4087-4097.
72. Christensen, M.O., Barthelmes, H.U., Boege, F. and Mielke, C. (2003) Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro. Nucleic Acids Res., 31, 7255-7263.
73. Redinbo, M.R., Champoux, J.J. and Hol, W.G. (2000) Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry, 39, 6832-6840.
74. Pond, C.D., Holden, J.A., Schnabel, P.C. and Barrows, L.R. (1997) Surface plasmon resonance analysis of topoisomerase I-DNA binding: effect of Mg2+ and DNA sequence. Anticancer Drugs, 8, 336-344.
75. Koster, D.A., Czerwinski, F., Halby, L., Crut, A., Vekhoff, P., Palle, K., Arimondo, P.B. and Dekker, N.H. (2008) Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence. Nucleic Acids Res., 36, 2301-2310.
76. Tanizawa, A., Kohn, K.W., Kohlhagen, G., Leteurtre, F. and Pommier, Y. (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34, 7200-7206.
77. Kjeldsen, E., Svejstrup, J.Q., Gromova, I.I., Alsner, J. and Westergaard, O. (1992) Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I.J. Mol. Biol., 228, 1025-1030.
78. Tanizawa, A., Fujimori, A., Fujimori, Y. and Pommier, Y. (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst., 86, 836-842.